Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 11:13 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » Canadian Stock Picks » Strong Buy: AQS(MC $13 M) 2 Marketed Drugs + 3 Drugs close to Approval = FANTASTIC OPP



Reply
 
Thread Tools Search this Thread
Old 09-20-2016, 03:13 PM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Default AQS(MC $13 M) 2 Marketed Drugs + 3 Drugs close to Approval = FANTASTIC OPP

Aequus Pharma AQS.V (MC $13 M) 2 Marketed Drugs + 3 close to Approval including a Potential Blockbuster = SUPER LIFETIME OPPORTUNITY !!!!

This undiscovered low float rocket is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Get some of this Goldmine before she gets discovered .Management alone holding over 16 Million shares Ceo bought 840k shares at 0.30 just a few days ago .GLTA


Aequus Pharma (AQS.V) (AQSZF)

Market-Cap: c$13.5 M
Price: 0.27

Shares out: 54 Million


Presentation August 2016
http://www.aequuspharma.ca/Investors...ust%202016.pdf


Marketed Products:

Tacrolimus IR

Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)


Vistitan
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.



Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017


Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017

NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)


AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.


Biohero is offline   1 thumbs up / 0 thumbs down. Rate this post Yes | No Reply With Quote
Old 09-29-2016, 08:53 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Good News

Aequus Obtains Ontario Provincial Listing for Vistitan(TM)
Aequus Obtains Ontario Provincial Listing for Vistitan(TM)


"This is a major milestone since the launch of PrVistitan™ as Ontario accounts for over 40% of prescription volume in the prostaglandin class of medications," said Ian Ball, Chief Commercial Officer at Aequus. "Improved access to PrVistitan™ in Canada's largest market is expected to drive revenues towards during the remainder of 2016 and beyond."
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-11-2017, 10:16 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Im back on this unknown and super brutally underpriced Gem after a conversation with Ceo janzen .. Here is a reply from last friday


djanzen@aequuspharma.ca Jan 6 at 10:13 PM

Hello Bernstein and Happy New Year… Thanks for your email.

The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.

Happy to chat if you would like to have a phone call…

Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 02-15-2017, 11:33 AM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great Video out today
https://www.youtube.com/watch?v=jV00WmYBtv4
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 02-16-2017, 10:33 PM   Nav to Top  #5
tank
Trader
 
tank's Avatar
 
Join Date: Nov 2015
Location: edmonton
Posts: 32
Favorites: "BDI" "BCM" "SQD"
Rep Power: 58
Reputation: 10
tank is on a distinguished road
Money Good Call!

clap clap Good call on this one!
tank is offline   Rate this post Yes | No Reply With Quote
Old 03-02-2017, 09:12 AM   Nav to Top  #6
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Good News out today ..Cannabinoid Patch =HUGE Potential

Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

VANCOUVER, BC--(Marketwired - March 02, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term sheet (the "Term Sheet") to acquire an exclusive world-wide license to a transdermal patch containing cannabinoids, for the use in epilepsy, Multiple Sclerosis (MS), and certain other neurological disorders.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-09-2017, 09:21 AM   Nav to Top  #7
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

The bought deal financing creates a fantastic buying opportunity.

There is a lot of big news on the way which will drive the sp much higher again like the AQS1301 topline results which are imminent(this month) and new Product acquisitions .The Stock is brutally undervalued with a laughable market cap of just c$20 million .

fundamentals after financing :

Marktcap: c$20.5 Million ( US$ 15.1 Million )
Cash: c$4.5 Million << enough untill mid 2018
Price 0.285

Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch...
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

The Company expects to report topline results from this multi-dose study in the first quarter of 2017.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-13-2017, 10:18 AM   Nav to Top  #8
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Financing is closed today and Aequus got the full amount of cash which is good News .

Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option
Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option


The Company has now cash untill mid 2018 excluding Product Sales and new Partner Deals . A lot of big news are on the way which could push the stock much higher . Management and Institutions alone holding almost 70% of Company Shares . AQS is a must have at these ridiculous low price. This one has the potential to run like Biosyent (RX.V) which went from 0.10 to over $10 now at $7.50 .


Market-Cap: c$20.5 Million (US$15.15 Million)
Cash: c$5.1 Million << enough untill mid 2018
Price: $0.22


Presentation
http://www.aequuspharma.ca/Investors...202016_web.pdf

UPCOMING MILESTONES :

AQS1301 topline results in 1Q 2017

Operational profitability estimated in 2017

File for CDN approval of Topiramate XR in 1H 2017

File for CDN approval of Oxcarbazepine XR in 1H 2017

Additional Product acquisitions in 2017

Partnership for AQS1301 in 2017

Two products launches to date (Tacrolimus IR and Vistitan™)

3 long-acting, transdermal programs in development, on track to file NDA in 2018


MUST Watch
https://www.youtube.com/watch?v=jV00WmYBtv4


Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada
Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada | Financial Post


James West: Sure. Have you built a pharmaceutical company before, Doug?

Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.

James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?

Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
Biohero is offline   1 thumbs up / 0 thumbs down. Rate this post Yes | No Reply With Quote
Old 04-03-2017, 09:06 AM   Nav to Top  #9
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

GREAT News out , this product alone could bring as much as $200 million in annual revenue and this unknown goldmine is value at laughable $14 million .This one has reallly 20 bagger potential if everything goes well .GL

Aequus Pharmaceuticals : Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
Aequus Pharmaceuticals : Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch | 4-Traders

The Abilify brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.


MUST WATCH to realize the MEGA MONSTER POTENTIAL HERE
https://www.youtube.com/watch?v=jV00WmYBtv4
Biohero is offline   1 thumbs up / 0 thumbs down. Rate this post Yes | No Reply With Quote
Old 04-06-2017, 11:38 AM   Nav to Top  #10
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 296
Favorites: Aapl celg onxx
Rep Power: 115
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Up she goes again and still terrible undervalued ...

Another product acquisition imminent , im very optimistic that this unknown stock will hit $1 before year end .


Must Watch to realize the mega potential here
https://www.youtube.com/watch?v=jV00WmYBtv4
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: AEZS ( MC $43 M) 8 Drugs in P2 /1x in P3 / 1x Awaiting FDA approval Biohero US Stock Picks 0 11-14-2013 07:00 AM
Strong Buy: IPCI -- 8 Drugs under review by FDA 2 of them will get Approval before Year End !!!! Biohero US Penny Stock Picks 0 08-01-2013 10:18 AM
Strong Buy: TBUFF (Mcap $19 M) 7 Drugs launched & 1 Potential Blockbuster close to Market Biohero US Penny Stock Picks 1 07-24-2013 01:03 PM
Strong Buy: (IPCI) 6 Drugs awaiting FDA Approval (Mcap 48 M) !!! Biohero US Stock Picks 0 02-03-2012 12:09 PM
Strong Buy: IGXT - FDA approval in 3Q (Mcap 31 M$) 10 Drugs in Pipeline !!! biotechmaster US Penny Stock Picks 20 11-11-2011 06:48 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On